exampl
vaccineinduc
enhanc
suscept
viru
infect
aberr
viral
pathogenesi
document
infect
member
differ
viru
famili
sever
mechan
mani
still
poorli
understood
basi
phenomenon
vaccin
develop
lentiviru
infect
gener
hivaid
particular
littl
success
certain
experiment
lentivir
vaccin
even
prove
counterproduct
render
vaccin
subject
suscept
infect
rather
protect
vaccineinduc
enhanc
suscept
infect
certain
virus
like
felin
coronaviru
dengu
viru
felin
immunodefici
viru
shown
antibodydepend
enhanc
ade
play
import
role
mechan
may
either
absenc
combin
ade
involv
consequ
vaccineinduc
enhanc
major
stumbl
block
develop
certain
flavi
corona
paramyxo
lentiviru
vaccin
also
recent
failur
develop
vaccin
hiv
may
least
part
attribut
induct
enhanc
suscept
infect
may
well
delic
balanc
induct
protect
immun
one
hand
induct
enhanc
suscept
present
paper
review
current
known
mechan
vaccineinduc
enhanc
suscept
viru
infect
aberr
viral
pathogenesi
coreceptor
interfer
viral
entri
vaccineinduc
antibodi
antivir
therapi
one
major
goal
develop
lentivir
intervent
strategi
spite
huge
invest
success
field
lentiviru
vaccin
develop
limit
case
use
experiment
lentivir
vaccin
prove
counterproduct
render
vaccin
subject
suscept
infect
review
report
exampl
vaccineinduc
enhanc
suscept
viru
infect
gener
lentiviru
infect
particular
well
current
known
mechan
may
underli
phenomenon
antibodydepend
enhanc
ade
viru
infect
increas
viral
entri
mechan
observ
virus
sever
famili
also
shown
play
import
role
natur
pathogenesi
review
see
probabl
bestknown
exampl
ade
infect
vitro
enhanc
dengu
viru
denv
member
flavivirida
famili
entri
viru
specif
antibodi
genu
flaviviru
famili
flavivirida
consist
arthropodborn
virus
murray
valley
enceph
viru
mvev
west
nile
viru
wnv
japanes
enceph
viru
jev
denv
four
serotyp
denv
describ
multipl
serotyp
cocircul
endem
area
infect
denv
serotyp
may
result
spectrum
clinic
sign
symptom
rang
mild
influenzalik
ill
known
dengu
fever
df
sever
form
diseas
character
coagulopathi
increas
vascular
permeabl
dengu
hemorrhag
fever
dhf
may
progress
hypovolem
shock
certain
patient
caus
dengu
shock
syndrom
dss
ade
first
describ
vitro
system
mvev
wnv
ade
subsequ
postul
halstead
colleagu
base
observ
dhf
dss
predominantli
seen
children
experienc
second
infect
heterolog
denv
serotyp
observ
incid
dhf
dss
peak
two
popul
young
children
one
peak
occur
infant
age
month
infect
denv
serotyp
differ
serotyp
infect
mother
previous
key
observ
sever
diseas
occur
infant
whose
matern
antibodi
declin
low
subneutr
level
peak
observ
young
children
experienc
earlier
usual
mild
subclin
infect
later
infect
differ
denv
serotyp
observ
led
conclus
preexist
immun
denv
could
predispos
individu
seriou
infect
heterolog
serotyp
denv
afford
protect
diseas
later
sever
epidemiolog
studi
provid
circumstanti
evid
role
preexist
humor
immun
pathogenesi
dhf
vitro
experi
show
denv
infect
could
enhanc
use
polyclon
antisera
rais
heterolog
denv
serotyp
furthermor
shown
administr
denvspecif
matern
antibodi
enhanc
sever
denv
infect
rhesu
macaqu
monkey
infect
presenc
antidenv
antibodi
develop
higher
level
viremia
longer
period
control
monkey
although
mani
detail
regard
fc
receptor
mediat
entri
denv
still
unclear
shown
play
import
role
effici
enhanc
denv
infect
cell
vitro
role
ade
denv
infect
remain
unknown
like
involv
well
expect
result
ade
viral
infect
would
increas
viral
load
like
caus
infect
higher
number
suscept
cell
altern
entri
may
modul
antivir
immun
respons
recent
studi
ross
river
viru
denv
show
entri
via
pathway
could
suppress
express
antivir
gene
enhanc
product
mononuclear
cell
vitro
contrast
entri
via
usual
cellular
receptor
affect
induct
antivir
effector
mechan
although
pathogenesi
dhfdss
elucid
ade
infect
hypothesi
remain
signific
concern
develop
safe
effect
vaccin
felin
corona
viru
fcov
infect
cat
usual
mild
also
lead
develop
chronic
immunemedi
diseas
high
fatal
rate
call
felin
infecti
periton
fip
fip
develop
upon
occurr
spontan
mutat
certain
region
fcov
genom
chang
cell
tropism
viru
allow
replic
macrophag
consid
larg
respons
fcov
infect
develop
rel
apathogen
chronic
immunemedi
diseas
fip
diseas
manifest
varieti
clinic
symptom
due
infect
multipl
organ
often
includ
central
nervou
system
earli
experi
shown
transfer
plasma
contain
hightitr
fcov
specif
antibodi
kitten
render
anim
suscept
rapidli
develop
fip
kitten
receiv
fcov
neg
serum
ade
infect
subsequ
shown
mediat
antibodi
direct
viral
spike
protein
immun
recombin
vaccinia
viru
prepar
express
fcov
protein
result
induct
sspecif
antibodi
respons
lowlevel
neutral
antibodi
titer
lead
enhanc
suscept
challeng
infect
young
cat
fip
fcov
primarili
target
cell
macrophagemonocyt
lineag
ade
thought
occur
bind
antibodybound
fcov
fc
receptor
cell
membran
collect
data
show
ade
mediat
sspecif
antibodi
increas
viral
entri
monocytesmacrophag
basi
enhanc
suscept
preimmun
cat
develop
fip
enhanc
respiratori
syncyti
viru
rsv
diseas
atyp
measl
observ
children
vaccin
formaldehyd
inactiv
alum
adjuv
candid
vaccin
sixti
upon
exposur
wild
type
rsv
measl
viru
respect
later
life
long
specul
aberr
antibodi
respons
viral
glycoprotein
basi
phenomenon
although
inde
neutral
serum
antibodi
respons
induc
vaccin
candid
rel
weak
shortliv
result
rapid
renew
suscept
infect
vaccin
mechan
ade
could
basi
observ
immunopatholog
besid
anomal
antibodi
respons
sever
differ
immunolog
respons
induc
either
formaldehyd
inactiv
vaccin
natur
infect
could
explain
observ
enhanc
phenomenon
absenc
specif
cytotox
tcell
respons
immun
complex
deposit
infect
tissu
increas
specif
prolif
lymphocyt
respons
bia
specif
immun
respons
toward
phenotyp
larg
conclud
basi
immun
infect
data
gener
preclin
studi
use
mous
macaqu
infect
model
virus
altern
gener
carbonyl
group
formaldehyd
treatment
vaccin
could
contribut
increas
sensit
infect
recent
shown
macaqu
model
formalininactiv
human
metapneumoviru
hmpv
also
member
paramyxovirida
famili
vaccin
propens
predispos
immunemedi
diseas
inactiv
rsv
mv
vaccin
fihmpvprim
monkey
develop
eosinophil
bronchiti
bronchiol
upon
challeng
like
rsv
mv
model
indic
hypersensit
respons
collect
data
provid
us
anim
model
enhanc
paramyxoviru
diseas
use
screen
new
gener
candid
vaccin
earli
stage
potenti
induct
enhanc
sensit
infect
also
vaccin
cat
candid
fiv
vaccin
enhanc
suscept
rather
protect
infect
observ
one
studi
passiv
transfer
experi
carri
demonstr
antibodi
probabl
respons
observ
enhanc
infect
similarli
vaccin
hors
eiav
recombin
proteininduc
enhanc
subsequ
infect
although
result
vitro
ade
assay
correl
observ
enhanc
infect
alreadi
earli
day
hiv
research
robinson
montefiori
describ
vitro
infect
viru
could
enhanc
viru
specif
antibodi
multipl
mechan
describ
may
caus
contribut
ade
hiv
infect
viru
complex
antibodi
may
captur
intern
fcr
complement
receptor
cr
process
may
may
bypass
natur
rout
via
chemokin
receptor
depend
experiment
condit
addit
receptor
may
provid
activ
signal
cell
bind
virusantibodi
complex
could
support
viru
endocytosi
increas
viru
product
enhanc
independ
fcr
cr
may
also
occur
neutral
antibodi
also
solubl
enhanc
viru
infect
induc
conform
chang
viral
envelop
bring
envelop
proxim
coreceptor
gener
prolong
contact
viru
target
cell
increas
chanc
receptor
bind
subsequ
fusion
occur
may
also
accomplish
deposit
antibodycompl
complex
cell
independ
cr
captur
via
format
fibril
also
siv
infect
macaqu
ade
infect
describ
sera
monkey
infect
ade
could
demonstr
observ
macaqu
vaccin
envelop
prepar
furthermor
report
plasma
obtain
infect
anim
enhanc
sivmac
infect
human
cell
line
depend
presenc
complement
manner
similar
complementmedi
ade
activ
observ
hivposit
human
sera
vitro
experi
describ
lentivirus
replic
best
activ
cell
immun
system
system
activ
immun
system
gener
result
enhanc
viru
replic
eg
opportunist
infect
higher
number
activ
target
cell
ie
tcell
cell
myeloid
lineag
like
account
viral
burst
observ
exampl
bacteri
product
may
activ
tcell
via
tolllik
receptor
tlr
possibl
also
direct
intracellular
interact
replic
enhanc
molecul
virus
eg
herpesvirus
hiv
shown
vitro
studi
given
rel
low
chanc
two
differ
virus
would
replic
cell
vivo
contribut
mechan
great
import
overal
viru
product
vaccin
infect
individu
pathogen
may
may
result
increas
replic
repeat
tcell
activ
sivinfect
monkey
also
shorten
surviv
anim
activ
immun
system
increas
number
activ
tcell
suscept
infect
rest
tcell
addit
augment
product
may
implic
increas
viral
load
infect
leukocyt
adhes
molecul
leukocyt
functionassoci
antigen
lfa
express
cell
may
increas
incorpor
intercellular
adhes
molecul
icam
viru
particl
bud
activ
tcell
addit
activ
tcell
may
also
role
activ
macrophag
recent
report
herp
viru
infect
mice
protect
listeria
monocytogen
yersinia
pesti
pathogenesi
via
activ
macrophag
contrast
cmv
infect
human
may
lead
increas
suscept
infect
dendrit
cell
key
player
gener
immun
respons
mani
dc
express
dcsign
ctype
lectin
captur
hiv
env
protein
hiv
bound
dcsign
may
follow
differ
pathway
lead
viru
destruct
mhcrestrict
antigen
present
infect
infect
matur
dc
ci
result
low
level
viru
product
interestingli
infect
may
also
occur
tran
dc
deliv
infecti
particl
tcell
interact
dc
regard
matur
dc
shown
increas
transmiss
virus
tcell
precis
involv
dcsign
process
still
unclear
regardless
molecul
involv
hiv
infect
tcell
greatli
enhanc
matur
dc
deliv
viru
dc
may
act
vehicl
like
trojan
hors
deliv
viru
environ
activ
tcell
immunolog
synaps
form
dc
tcell
may
facilit
infect
tcell
addit
virion
less
suscept
inactiv
associ
dc
sinc
discoveri
numer
attempt
develop
effect
safe
vaccin
fiv
made
recent
whole
inactiv
cell
vaccin
contain
two
fiv
subtyp
licens
us
effect
breadth
fiv
vaccin
still
subject
debat
passiv
adopt
transfer
studi
suggest
viru
neutral
cellular
immun
respons
basi
report
efficaci
nevertheless
virtual
fiv
vaccin
evalu
far
fail
induc
protect
immun
sever
induc
increas
suscept
infect
first
report
enhanc
infect
vaccin
fiv
date
cat
vaccin
iscom
prepar
contain
either
purifi
fiv
particl
recombin
fiv
gag
protein
well
cat
vaccin
formaldehyd
fix
infect
cell
becam
virem
week
earlier
control
cat
furthermor
fiv
vaccin
cat
becam
virem
upon
challeng
case
control
cat
experi
vaccin
use
shown
immunogen
although
envspecif
viru
neutral
antibodi
respons
detect
day
challeng
cat
vaccin
infect
cell
vaccin
anoth
studi
vaccin
synthet
peptid
repres
linear
epitop
loop
fiv
envelop
protein
freund
adjuv
induc
viru
neutral
antibodi
predispos
cat
acceler
viru
replic
upon
challeng
infect
anoth
studi
iscombas
vaccin
contain
sever
fiv
envelop
glycoprotein
prepar
cat
receiv
eukaryot
express
env
glycoprotein
develop
envspecif
viru
neutral
antibodi
cat
becam
virem
least
week
earlier
control
cat
increas
suscept
infect
also
seen
cat
transfer
plasma
obtain
vaccin
cat
collect
result
suggest
fiv
envelop
specif
antibodi
involv
vaccineinduc
enhanc
infect
particular
antibodi
region
envelop
protein
associ
observ
enhanc
infect
followup
studi
recombin
envelop
protein
prepar
part
encompass
region
delet
vaccin
engin
protein
still
predispos
increas
suscept
infect
conclud
also
antibodi
direct
epitop
outsid
region
abl
caus
enhanc
infect
attempt
immun
cat
antigen
prepar
mimic
natur
conform
close
use
formaldehyd
fix
fiv
infect
autolog
pbmc
evalu
despit
induct
gag
envelop
specif
antibodi
vaccin
cat
protect
infect
suscept
infect
control
cat
immun
fix
uninfect
pbmc
anoth
studi
use
formaldehyd
inactiv
fiv
vaccin
induc
poorli
viru
neutral
antibodi
respons
enhanc
infect
lowdos
challeng
infect
observ
studi
richardson
et
al
gener
immun
activ
suggest
altern
mechan
induct
vaccinemedi
increas
suscept
fiv
infect
vaccin
dna
fiv
env
gene
express
induc
weak
envspecif
antibodi
respons
predispos
enhanc
infect
specul
immun
increas
target
cell
popul
fiv
infect
mechan
similar
describ
heterolog
vaccin
infect
subject
describ
enhanc
fiv
infect
associ
increas
suscept
lymphocyt
obtain
vaccin
ex
vivo
fiv
infect
induct
env
specif
thelper
cell
respons
collect
result
suggest
fiv
vaccin
addit
ade
also
mechan
may
contribut
increas
suscept
fiv
infect
schwartz
suggest
induct
expans
specif
cell
vaccin
might
constitut
seriou
confound
factor
hiv
vaccin
develop
inde
sinc
shown
preferenti
target
specif
cell
infect
individu
likewis
enhanc
fiv
infect
immun
activ
may
result
activ
expans
cell
primari
receptor
fiv
tcell
activ
marker
costimulatori
molecul
express
strictli
confin
tcell
tcell
constitut
major
target
fiv
earli
infect
expans
subpopul
eg
vaccin
would
provid
viru
ideal
opportun
replic
furthermor
fiv
coreceptor
molecul
express
activ
bcell
monocyt
demonstr
increas
express
cell
line
result
enhanc
fiv
replic
vitro
recent
use
flow
cytometr
analysi
cell
popul
ex
vivo
clear
posit
associ
express
fiv
infect
demonstr
although
result
also
suggest
exist
mechan
infect
summari
select
express
induc
vaccin
fiv
pathogen
may
support
fiv
replic
earli
stage
infect
lymphocyt
essenti
sustain
memori
immun
respons
parallel
target
strain
hiv
memori
tcell
exclus
express
earli
infect
activ
subsequ
signal
via
upregul
express
may
induc
cellular
chang
favour
viral
integr
replic
lymphat
system
thu
facilit
dissemin
fiv
infect
recent
studi
suggest
felin
dendrit
cell
fedc
play
role
transmiss
fiv
compar
human
dc
hiv
infect
shown
vitro
fedc
increas
fiv
infect
rest
cell
particular
activ
tcell
reminisc
vivo
result
obtain
hiv
siv
earli
studi
show
fiv
interact
ctype
lectin
receptor
like
human
dcsign
interact
facilit
fiv
infect
tran
similar
mechan
describ
see
furthermor
shown
fedc
express
primari
receptor
lesser
extent
coreceptor
although
less
effici
lymphocyt
fedc
support
product
fiv
replic
fedc
may
contribut
infect
activ
tcell
immedi
transfer
involv
exosom
endolysosom
pathway
transfer
de
novo
gener
fiv
particl
product
infect
dc
collect
data
suggest
addit
role
fedc
vaccineinduc
enhanc
infect
might
facilit
infect
vaccineinduc
activ
tcell
vaccin
poni
eiav
inactiv
whole
viru
envelop
subunit
vaccin
prepar
complet
protect
anim
homolog
challeng
infect
fail
induc
protect
immun
infect
heterolog
viru
strain
howev
anim
vaccin
inactiv
whole
viru
level
viral
replic
challeng
heterolog
eiav
strain
mere
suppress
moreov
poni
vaccin
envelop
subunit
vaccin
exhibit
sign
enhanc
diseas
upon
heterolog
challeng
infect
use
recombin
envelop
protein
fail
afford
protect
infect
homolog
viru
predispos
enhanc
viru
replic
diseas
anim
heterolog
challeng
infect
vaccineinduc
envspecif
antibodi
titer
correl
outcom
challeng
infect
mechan
underli
observ
enhanc
eiav
infect
remain
elucid
vaccin
rhesu
macaqu
attenu
varicellazost
viru
vaccin
express
siv
env
elicit
nonneutr
envbind
antibodi
littl
envspecif
cytotox
lymphocyt
respons
upon
challeng
infect
heterolog
siv
strain
increas
level
siv
replic
rapid
lymphocyt
deplet
acceler
progress
toward
aid
observ
anim
compar
control
anim
correl
increas
tcell
prolifer
immedi
siv
challeng
like
result
anamnest
respons
siv
antigen
indic
activ
virusspecif
tcell
absenc
adequ
tcell
respons
may
enhanc
viru
replic
diseas
find
corrobor
increas
viral
set
point
acceler
diseas
progress
macaqu
treat
activ
tcell
concomit
enhanc
tcell
respons
siv
capabl
contain
viru
replic
similarli
acceler
diseas
progress
observ
macaqu
vaccin
defect
proviru
recombin
sendai
express
gag
although
latter
approach
reduc
viral
load
acut
infect
vaccin
anim
develop
increas
viral
load
chronic
infect
progress
rapidli
toward
aid
increas
viremia
independ
observ
sivspecif
tcell
respons
correl
declin
sivspecif
tcell
clinic
trial
human
involv
virtual
approach
current
avail
viral
vaccin
develop
carri
past
decad
howev
phase
phase
ii
trial
due
design
trial
enhanc
phenomena
would
encount
recent
number
phase
iii
trial
conduct
seroneg
volunt
high
risk
hiv
infect
use
monomer
prepar
outcom
trial
far
encourag
limit
induct
hiv
neutral
antibodi
evid
protect
howev
trial
far
indic
ade
form
enhanc
suscept
found
recent
phase
iib
efficaci
trial
conduct
similar
highrisk
popul
attenu
recombin
candid
vaccin
express
hiv
gag
pol
nef
gene
also
trial
protect
efficaci
observ
contrast
signific
trend
toward
increas
infect
rate
observ
volunt
high
preexist
antibodi
titer
compar
individu
low
preexist
titer
due
setup
trial
complex
requir
statist
analys
thorough
assess
possibl
confound
factor
pend
http
present
step
trial
efficaci
analys
although
two
categori
vaccine
defin
basi
antibodi
titer
unclear
specif
antibodi
could
enhanc
suscept
hiv
infect
propos
antibodi
would
redirect
vaccin
cell
type
could
result
differ
type
immun
would
result
enhanc
transmiss
hiv
vaccine
remain
elucid
anoth
hypothesi
would
antibodi
level
person
natur
infect
reflect
overal
immun
viru
would
impli
presenc
increas
number
specif
memori
tcell
cell
would
readili
reactiv
vaccin
recombin
thu
creat
abund
pool
suscept
cell
target
incom
hiv
seroposit
person
yet
anoth
hypothesi
would
group
highest
titer
contain
larger
percentag
peopl
recent
contact
either
first
infect
reinfect
would
lead
presenc
activ
memori
tcell
includ
cell
may
contribut
increas
suscept
toward
hiv
infect
two
last
hypothes
would
valid
would
prohibit
use
mani
viral
vector
carrier
lentivir
antigen
vaccin
sinc
mani
attenu
vector
exploit
date
base
close
relat
virus
commonli
circul
human
popul
crossreact
immun
respons
frequent
present
result
activ
immun
system
may
lead
enhanc
hiv
replic
rather
provid
protect
could
also
pose
problem
person
sinc
infect
wild
type
viru
upon
vaccin
vector
viru
result
enhanc
immun
viru
enlarg
pool
activ
tcell
pool
might
increas
suscept
hiv
coinfect
occur
area
hiv
endem
collect
data
obtain
candidatevaccin
clinic
trial
disappoint
far
none
candid
vaccin
test
afford
protect
even
wors
even
enhanc
suscept
hiv
infect
better
understand
mechan
underli
vaccineinduc
protect
enhanc
word
correl
protect
immun
pathogenesi
urgent
need
advanc
field
hiv
vaccin
develop
vaccineinduc
enhanc
suscept
viru
infect
aberr
pathogenesi
viru
infect
document
infect
member
sever
viru
famili
therefor
uniqu
lentivirus
although
identifi
singl
respons
mechan
virushost
relationship
difficult
review
attempt
made
identifi
defin
potenti
mechan
involv
phenomena
see
tabl
firstli
ade
play
import
role
vaccineinduc
enhanc
fiv
fcov
possibl
dengu
viru
infect
secondli
mechan
involv
immun
activ
mainli
via
activ
memori
tcell
necessarili
viru
specif
seen
lentivir
system
activ
dc
may
play
addit
role
mechan
case
hiv
possibl
also
fiv
thirdli
bias
andor
aberr
tcell
respons
often
involv
eosinophilia
may
involv
observ
vaccineinduc
enhanc
diseas
paramyxoviru
infect
rsv
atyp
mv
vaccineinduc
enhanc
infect
diseas
pathogenesi
major
stumbl
block
develop
certain
flavi
coronaand
paramyxoviru
vaccin
also
tabl
mechan
enhanc
suscept
viru
infect
aberr
viral
pathogenesi
mediat
preexist
immun
viru
famili
recent
failur
develop
safe
effect
vaccin
hiv
least
part
attribut
induct
enhanc
rather
induct
protect
toward
viru
replic
current
vaccin
candid
may
well
delic
balanc
two
outcom
final
result
vaccin
like
determin
sum
paramet
confound
factor
may
involv
includ
type
candid
vaccin
use
viral
andor
host
factor
coinfect
time
vaccin
research
specif
aim
identif
mechan
lead
either
protect
enhanc
would
greatli
stimul
abil
design
safe
effect
vaccin
lentiviru
infect
specif
hiv
vaccin
